Pulmonx Co. (NASDAQ:LUNG) CEO Steven S. Williamson Sells 9,923 Shares

Pulmonx Co. (NASDAQ:LUNG - Get Free Report) CEO Steven S. Williamson sold 9,923 shares of the stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $3.13, for a total value of $31,058.99. Following the sale, the chief executive officer now owns 366,115 shares of the company's stock, valued at $1,145,939.95. This trade represents a 2.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Pulmonx Stock Up 6.7%

NASDAQ:LUNG traded up $0.20 during mid-day trading on Friday, reaching $3.17. The stock had a trading volume of 1,036,300 shares, compared to its average volume of 316,044. The stock has a market cap of $127.62 million, a P/E ratio of -2.20 and a beta of 0.52. The business's 50 day moving average is $4.27 and its 200 day moving average is $5.95. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. Pulmonx Co. has a fifty-two week low of $2.83 and a fifty-two week high of $9.37.

Pulmonx (NASDAQ:LUNG - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.01. The company had revenue of $22.54 million for the quarter, compared to analyst estimates of $22.03 million. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. As a group, sell-side analysts predict that Pulmonx Co. will post -1.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

LUNG has been the subject of a number of recent research reports. Canaccord Genuity Group cut their price objective on Pulmonx from $16.00 to $15.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. D. Boral Capital restated a "buy" rating and issued a $17.00 target price on shares of Pulmonx in a report on Thursday, May 1st. Morgan Stanley assumed coverage on Pulmonx in a report on Monday, March 10th. They issued an "equal weight" rating for the company. Jefferies Financial Group assumed coverage on Pulmonx in a report on Monday, March 10th. They issued a "buy" rating for the company. Finally, Piper Sandler restated an "overweight" rating and issued a $9.00 target price (down previously from $10.00) on shares of Pulmonx in a report on Thursday, May 1st. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $11.53.

Hedge Funds Weigh In On Pulmonx

Several hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets acquired a new position in Pulmonx during the fourth quarter worth $43,000. ProShare Advisors LLC acquired a new position in Pulmonx during the fourth quarter worth $72,000. Stifel Financial Corp acquired a new position in Pulmonx during the fourth quarter worth $81,000. Vontobel Holding Ltd. acquired a new position in Pulmonx during the first quarter worth $82,000. Finally, SG Americas Securities LLC increased its position in Pulmonx by 27.0% during the fourth quarter. SG Americas Securities LLC now owns 15,555 shares of the company's stock worth $106,000 after buying an additional 3,310 shares during the last quarter. 91.04% of the stock is owned by institutional investors and hedge funds.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.